TRHC TABULA RASA HEALTHCARE

Tabula Rasa HealthCare® Names Frank Sparacino SVP Investor Relations and Corporate Development

Tabula Rasa HealthCare® Names Frank Sparacino SVP Investor Relations and Corporate Development

Veteran Healthcare Technology Research Analyst Joins TRHC to Lead Investor Relations

MOORESTOWN, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare®, Inc. (“TRHC”) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, has named Frank Sparacino Senior Vice President of Investor Relations and Corporate Development. Sparacino will be responsible for overseeing TRHC’s interactions with the investment community and formalizing a corporate development function.

“Frank is the ideal candidate to take on this important new role with Tabula Rasa HealthCare. He is a former sell side equity research analyst focused on the healthcare technology space and has covered Tabula Rasa for the past three years. During that time, we observed how dedicated Frank was to establishing a deep understanding of the company, our value proposition and our market opportunity,” said Chief Financial Officer, Brian W. Adams. “We could not be happier to have Frank on board with TRHC.”

Sparacino comes to TRHC from First Analysis, headquartered in Chicago, IL, where he spent the last 20 years developing their healthcare technology research platform. In this role, he has received multiple awards recognizing his ability to identify top performing companies. As a partner on the firm’s venture capital fund, Sparacino lead investments in the healthcare technology space and served as the firm’s representative on various boards of directors.

When asked what brought Sparacino to TRHC, Sparacino said, “I think highly of the team, the company’s mission, and the long-term market potential around the medication safety solutions TRHC has developed. I am excited about this new role and the opportunity to join an innovative healthcare technology company that is also a market maker with their medication safety science.”  

Prior to First Analysis, Sparacino held positions with Barrington Research Associates, UBS Asset Management and KPMG. He is a Chartered Financial Analyst (CFA) and Certified Public Accountant (CPA).

About Tabula Rasa HealthCare

TRHC (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations.  For more information, visit .

Media Contact

Dianne Semingson



T: (215) 870-0829
Investors

Frank Sparacino



T: (866) 648-2767
  
Amanda Bednar



T: (856) 912-5714
 

EN
26/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TABULA RASA HEALTHCARE

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: July 27, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: July 25, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Tabula Rasa Healthcare Inc: 3 directors

A director at Tabula Rasa Healthcare Inc bought 2,000 shares at 5.630USD and the significance rating of the trade was 34/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch